0001214659-23-016477.txt : 20240118 0001214659-23-016477.hdr.sgml : 20240118 20231215110201 ACCESSION NUMBER: 0001214659-23-016477 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20231215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biodexa Pharmaceuticals Plc CENTRAL INDEX KEY: 0001643918 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1 CASPIAN POINT STREET 2: CASPIAN WAY CITY: CARDIFF STATE: X0 ZIP: CF10 4DQ BUSINESS PHONE: 44 (0)1235 888300 MAIL ADDRESS: STREET 1: 1 CASPIAN POINT STREET 2: CASPIAN WAY CITY: CARDIFF STATE: X0 ZIP: CF10 4DQ FORMER COMPANY: FORMER CONFORMED NAME: Midatech Pharma Plc DATE OF NAME CHANGE: 20150602 CORRESP 1 filename1.htm

 

Biodexa Pharmaceuticals Plc

1 Caspian Point

Caspian Way

Cardiff, CF10 4DQ

United Kingdom

 

December 15, 2023

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Doris Stacey Gama

 

Re:Biodexa Pharmaceuticals Plc (the “Company”)
Registration Statement on Form F-1 (File No. 333-274895)
Originally Filed October 6, 2023

 

Ladies and Gentlemen:

 

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended (the “Act”), the Company hereby respectfully requests that the Securities and Exchange Commission accelerates the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) and declares the Registration Statement effective as of 5:30 p.m. Eastern Time, on December 18, 2023, or as soon as practicable thereafter. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

 

We request that we be notified of such effectiveness by a telephone call to Jason S. McCaffrey at (617) 348-4416 of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, and we request that such effectiveness also be confirmed in writing.

 

  Very truly yours,
   
  BIODEXA PHARMACEUTICALS PLC
     
     
  By: /s/ Stephen Stamp
    Name: Stephen Stamp
    Title: Chief Executive Officer & Chief Financial Officer

 

 

cc: Jason S. McCaffrey, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.